Cargando…

Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis

OBJECTIVE: Cases of inflammatory bowel disease (IBD) during treatment with interleukin (IL)-17 antagonists have been reported from trials in psoriasis, psoriatic arthritis, and ankylosing spondylitis. The aim of this study was to assess the overall risk for development of IBD due to IL-17 inhibition...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burisch, Johan, Eigner, Wolfgang, Schreiber, Stefan, Aletaha, Daniel, Weninger, Wolfgang, Trauner, Michael, Reinisch, Walter, Narula, Neeraj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252630/ https://www.ncbi.nlm.nih.gov/pubmed/32459816 http://dx.doi.org/10.1371/journal.pone.0233781

Ejemplares similares

Is hypertension an extra‐intestinal manifestation of inflammatory bowel disease?
por: Burisch, Johan
Publicado: (2023)

Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease
por: Krawiec, Paulina, et al.
Publicado: (2020)

Role of endoscopy in inflammatory bowel disease
por: Bharadwaj, Shishira, et al.
Publicado: (2018)

Epidemiology of inflammatory bowel disease in racial and ethnic migrant groups
por: Misra, Ravi, et al.
Publicado: (2018)

Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors
por: Fieldhouse, Keira A, et al.
Publicado: (2020)

Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease
por: Pedersen, Natalia, et al.
Publicado: (2017)

Endogenous interleukin-10 constrains Th17 cells in patients with inflammatory bowel disease
por: Wilke, Cailin M, et al.
Publicado: (2011)

Interleukin-17 and inflammatory bowel disease: a 2-sample Mendelian randomization study
por: Cai, Yangke, et al.
Publicado: (2023)

The Faroese IBD Study: Incidence of Inflammatory Bowel Diseases Across 54 Years of Population-based Data
por: Hammer, Turid, et al.
Publicado: (2016)

Impact of Digital Health Monitoring in the Management of Inflammatory Bowel Disease
por: Zhen, Jamie, et al.
Publicado: (2021)

Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease
por: Kärnsund, Sofia, et al.
Publicado: (2020)

Targeting the Interleukin-23/Interleukin-17 Inflammatory Pathway: Successes and Failures in the Treatment of Axial Spondyloarthritis
por: Wang, Runsheng, et al.
Publicado: (2021)

Smell and Taste in Inflammatory Bowel Disease
por: Steinbach, Silke, et al.
Publicado: (2013)

Tofacitinib in the treatment of ulcerative colitis: A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology (ÖGGH)
por: Kutschera, Maximilian, et al.
Publicado: (2022)

Patient Reported Outcomes in Chronic Inflammatory Diseases: Current State, Limitations and Perspectives
por: Tran, Florian, et al.
Publicado: (2021)

Interleukin-17 in human inflammatory diseases
por: Shabgah, Arezoo Gowhari, et al.
Publicado: (2014)

Validation of claims-based indicators used to identify flare-ups in inflammatory bowel disease
por: Burisch, Johan, et al.
Publicado: (2021)

Letter to the Editor Regarding ‘Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland’
por: Muñoz, Manuel, et al.
Publicado: (2021)

Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial
por: D’Haens, Geert, et al.
Publicado: (2023)

High Intestinal and Systemic Levels of Interleukin-23/T-Helper 17 Pathway in Chinese Patients with Inflammatory Bowel Disease
por: Song, Lu, et al.
Publicado: (2013)

Interleukin-6 compared to the other Th17/Treg related cytokines in inflammatory bowel disease and colorectal cancer
por: Velikova, Tsvetelina Veselinova, et al.
Publicado: (2020)

Is there a relation between vitamin D, interleukin-17, and bone mineral density in patients with inflammatory bowel disease?
por: Krela-Kazmierczak, Iwona, et al.
Publicado: (2018)

Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
por: Schreiber, Stefan, et al.
Publicado: (2022)

Interleukin-17 in Chronic Inflammatory Neurological Diseases
por: Milovanovic, Jelena, et al.
Publicado: (2020)

Interleukin – 17 and Interleukin-10 as Inflammatory and Prevention Biomarkers in Periimplant Diseases
por: Farhad, Shirin Zahra, et al.
Publicado: (2019)

Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
por: Schreiber, Stefan, et al.
Publicado: (2022)

Interleukin‐17‐producing γδ T (γδ17) cells in inflammatory diseases
por: Akitsu, Aoi, et al.
Publicado: (2018)

Polymorphisms in the Toll-Like Receptor and the IL-23/IL-17 Pathways Were Associated with Susceptibility to Inflammatory Bowel Disease in a Danish Cohort
por: Bank, Steffen, et al.
Publicado: (2015)

Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
por: Saad Alshahrani, Abdulaziz, et al.
Publicado: (2023)

Interleukin-17 and interleukin-18 levels in different stages of inflammatory periodontal disease
por: Chitrapriya, Muthugounder Nalanaswamy, et al.
Publicado: (2015)

Expression of Interleukin-26 is upregulated in inflammatory bowel disease
por: Fujii, Makoto, et al.
Publicado: (2017)

The anti-inflammatory and protective role of interleukin-38 in inflammatory bowel disease
por: Ohno, Masashi, et al.
Publicado: (2022)

Interleukin-17 inhibits Adult Hippocampal Neurogenesis
por: Liu, Qiang, et al.
Publicado: (2014)

Interleukin-17 in Various Ocular Surface Inflammatory Diseases
por: Kang, Min Ho, et al.
Publicado: (2011)

Adverse Events Related to SARS-CoV-2 Vaccine in a Nationwide Cohort of Patients With Inflammatory Bowel Disease
por: Mahmud, Nadim, et al.
Publicado: (2022)

Impact of Vedolizumab on Extraintestinal Manifestations in Inflammatory Bowel Disease: Results From a Descriptive, Retrospective, Real-world Study
por: Kopylov, Uri, et al.
Publicado: (2023)

A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease
por: Reinisch, Walter, et al.
Publicado: (2015)

Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial
por: Ankersen, Dorit Vedel, et al.
Publicado: (2019)

Serum Interleukin (IL)-23 and IL-17 Profile in Inflammatory Bowel Disease (IBD) Patients Could Differentiate between Severe and Non-Severe Disease
por: Lucaciu, Laura A., et al.
Publicado: (2021)

Ethnic differences in inflammatory bowel disease: Results from the United Kingdom inception cohort epidemiology study
por: Misra, Ravi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a8tcp201458ioe0q40oqro27pk